Cargando…
Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes
Background and Objectives: The main cause of the vision loss in diabetics is the development of diabetic macular edema, regardless of the stage of diabetic retinopathy. The paper aimed to examine whether the additional intravitreal application of triamcinolone acetonide to continuous anti-vascular e...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220700/ https://www.ncbi.nlm.nih.gov/pubmed/37241214 http://dx.doi.org/10.3390/medicina59050982 |
_version_ | 1785049280399015936 |
---|---|
author | Petrovic, Nenad Todorovic, Dusan Sarenac Vulovic, Tatjana Sreckovic, Suncica Zivic, Fatima Risimic, Dijana |
author_facet | Petrovic, Nenad Todorovic, Dusan Sarenac Vulovic, Tatjana Sreckovic, Suncica Zivic, Fatima Risimic, Dijana |
author_sort | Petrovic, Nenad |
collection | PubMed |
description | Background and Objectives: The main cause of the vision loss in diabetics is the development of diabetic macular edema, regardless of the stage of diabetic retinopathy. The paper aimed to examine whether the additional intravitreal application of triamcinolone acetonide to continuous anti-vascular endothelial growth factor therapy could improve therapeutic outcomes for pseudophakic eyes with persistent diabetic macular edema. Materials and Methods: twenty-four pseudophakic eyes with refractory diabetic macular edema, that had appeared despite three previously administered intravitreal injections of aflibercept, were divided into two groups (twelve eyes in each group). The first group continued to have aflibercept administered according to a fixed dosing regimen (once in two months). Triamcinolone acetonide 10 mg/0.1 mL (administered once per four months) was included for the second group, i.e., their treatment continued with a combination of aflibercept + triamcinolone acetonide. Results: The reduction in central macular thickness was higher in the eyes treated with combined therapy (aflibercept + triamcinolone acetonide) compared with the use of aflibercept alone during the entire 12-month follow-up period (3rd month p = 0.019; 6th month p = 0.023; 9th month p = 0.027; 12th month p = 0.031). As was evident from the p-values, the differences were statistically significant. No statistically significant difference was recorded for visual acuity: 3rd month p = 0.423; 6th month p = 0.392; 9th month p = 0.413; 12th month p = 0.418. Conclusions: Combined anti-vascular endothelial growth factor and steroid therapy leads to a better anatomical outcome of persistent diabetic macular edema in pseudophakic eyes, but does not lead to a more significant improvement in visual acuity than continuous anti-VEGF therapy alone. |
format | Online Article Text |
id | pubmed-10220700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102207002023-05-28 Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes Petrovic, Nenad Todorovic, Dusan Sarenac Vulovic, Tatjana Sreckovic, Suncica Zivic, Fatima Risimic, Dijana Medicina (Kaunas) Article Background and Objectives: The main cause of the vision loss in diabetics is the development of diabetic macular edema, regardless of the stage of diabetic retinopathy. The paper aimed to examine whether the additional intravitreal application of triamcinolone acetonide to continuous anti-vascular endothelial growth factor therapy could improve therapeutic outcomes for pseudophakic eyes with persistent diabetic macular edema. Materials and Methods: twenty-four pseudophakic eyes with refractory diabetic macular edema, that had appeared despite three previously administered intravitreal injections of aflibercept, were divided into two groups (twelve eyes in each group). The first group continued to have aflibercept administered according to a fixed dosing regimen (once in two months). Triamcinolone acetonide 10 mg/0.1 mL (administered once per four months) was included for the second group, i.e., their treatment continued with a combination of aflibercept + triamcinolone acetonide. Results: The reduction in central macular thickness was higher in the eyes treated with combined therapy (aflibercept + triamcinolone acetonide) compared with the use of aflibercept alone during the entire 12-month follow-up period (3rd month p = 0.019; 6th month p = 0.023; 9th month p = 0.027; 12th month p = 0.031). As was evident from the p-values, the differences were statistically significant. No statistically significant difference was recorded for visual acuity: 3rd month p = 0.423; 6th month p = 0.392; 9th month p = 0.413; 12th month p = 0.418. Conclusions: Combined anti-vascular endothelial growth factor and steroid therapy leads to a better anatomical outcome of persistent diabetic macular edema in pseudophakic eyes, but does not lead to a more significant improvement in visual acuity than continuous anti-VEGF therapy alone. MDPI 2023-05-19 /pmc/articles/PMC10220700/ /pubmed/37241214 http://dx.doi.org/10.3390/medicina59050982 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Petrovic, Nenad Todorovic, Dusan Sarenac Vulovic, Tatjana Sreckovic, Suncica Zivic, Fatima Risimic, Dijana Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes |
title | Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes |
title_full | Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes |
title_fullStr | Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes |
title_full_unstemmed | Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes |
title_short | Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes |
title_sort | combined treatment of persistent diabetic macular edema with aflibercept and triamcinolone acetonide in pseudophakic eyes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220700/ https://www.ncbi.nlm.nih.gov/pubmed/37241214 http://dx.doi.org/10.3390/medicina59050982 |
work_keys_str_mv | AT petrovicnenad combinedtreatmentofpersistentdiabeticmacularedemawithafliberceptandtriamcinoloneacetonideinpseudophakiceyes AT todorovicdusan combinedtreatmentofpersistentdiabeticmacularedemawithafliberceptandtriamcinoloneacetonideinpseudophakiceyes AT sarenacvulovictatjana combinedtreatmentofpersistentdiabeticmacularedemawithafliberceptandtriamcinoloneacetonideinpseudophakiceyes AT sreckovicsuncica combinedtreatmentofpersistentdiabeticmacularedemawithafliberceptandtriamcinoloneacetonideinpseudophakiceyes AT zivicfatima combinedtreatmentofpersistentdiabeticmacularedemawithafliberceptandtriamcinoloneacetonideinpseudophakiceyes AT risimicdijana combinedtreatmentofpersistentdiabeticmacularedemawithafliberceptandtriamcinoloneacetonideinpseudophakiceyes |